Guggenheim Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.52M Sell
31,709
-3,411
-10% -$147K 0.01% 839
2026
Q1
$1.29M Buy
35,120
+2,835
+9% +$134K 0.01% 886
2025
Q4
$1.64M Buy
32,285
+2,892
+10% +$148K 0.01% 735
2025
Q3
$1.63M Buy
29,393
+3,259
+12% +$191K 0.01% 741
2025
Q2
$1.8M Sell
26,134
-1,776
-6% -$121K 0.01% 682
2025
Q1
$1.94M Buy
27,910
+5,791
+26% +$478K 0.02% 648
2024
Q4
$1.9M Sell
22,119
-6,428
-23% -$695K 0.02% 670
2024
Q3
$3.4M Sell
28,547
-6,861
-19% -$915K 0.02% 652
2024
Q2
$5.05M Buy
35,408
+2,546
+8% +$337K 0.04% 513
2024
Q1
$4.22M Sell
32,862
-489
-1% -$58.2K 0.03% 612
2023
Q4
$3.45M Sell
33,351
-9,614
-22% -$951K 0.03% 661
2023
Q3
$3.91M Sell
42,965
-1,715
-4% -$151K 0.03% 572
2023
Q2
$3.62M Sell
44,680
-11,230
-20% -$917K 0.03% 640
2023
Q1
$4.45M Buy
55,910
+13,690
+32% +$971K 0.04% 561
2022
Q4
$2.86M Sell
42,220
-2,984
-7% -$175K 0.03% 725
2022
Q3
$2.25M Buy
45,204
+1,036
+2% +$55.5K 0.02% 789
2022
Q2
$2.46M Buy
44,168
+2,058
+5% +$114K 0.02% 810
2022
Q1
$2.34M Buy
42,110
+1,550
+4% +$79.5K 0.01% 938
2021
Q4
$2.27M Sell
40,560
-3,910
-9% -$212K 0.01% 997
2021
Q3
$2.13M Buy
44,470
+1,668
+4% +$80.6K 0.01% 1024
2021
Q2
$1.79M Sell
42,802
-2,518
-6% -$97.6K 0.01% 1153
2021
Q1
$1.53M Buy
45,320
+428
+1% +$15.2K 0.01% 1174
2020
Q4
$1.57M Sell
44,892
-21,270
-32% -$735K 0.01% 1094
2020
Q3
$2.3M Sell
66,162
-6,032
-8% -$201K 0.02% 834
2020
Q2
$2.36M Buy
72,194
+1,940
+3% +$61.9K 0.02% 814
2020
Q1
$2.12M Sell
70,254
-14,536
-17% -$433K 0.02% 768
2019
Q4
$2.45M Sell
84,790
-30,268
-26% -$838K 0.02% 961
2019
Q3
$2.97M Sell
115,058
-21,030
-15% -$532K 0.02% 846
2019
Q2
$3.47M Sell
136,088
-36,446
-21% -$901K 0.03% 792
2019
Q1
$4.51M Buy
172,534
+32,830
+23% +$807K 0.04% 673
2018
Q4
$3.22M Buy
139,704
+12,796
+10% +$284K 0.03% 791
2018
Q3
$2.99M Sell
126,908
-1,214
-0.9% -$29.6K 0.02% 1021
2018
Q2
$2.95M Sell
128,122
-21,930
-15% -$521K 0.02% 1022
2018
Q1
$3.69M Sell
150,052
-6,998
-4% -$184K 0.01% 1190
2017
Q4
$4.21M Buy
157,050
+18,098
+13% +$460K 0.01% 1130
2017
Q3
$3.35M Buy
138,952
+30,332
+28% +$685K 0.01% 1305
2017
Q2
$2.33M Buy
108,620
+33,460
+45% +$675K 0.01% 1520
2017
Q1
$1.29M Buy
75,160
+4,690
+7% +$81.7K ﹤0.01% 1961
2016
Q4
$1.26M Buy
70,470
+2,884
+4% +$52.3K ﹤0.01% 2011
2016
Q3
$1.41M Buy
67,586
+9,396
+16% +$233K ﹤0.01% 1859
2016
Q2
$1.56M Buy
58,190
+10,254
+21% +$281K ﹤0.01% 1734
2016
Q1
$1.3M Sell
47,936
-5,354
-10% -$143K ﹤0.01% 1876
2015
Q4
$1.55M Sell
53,290
-150,594
-74% -$4.17M ﹤0.01% 1797
2015
Q3
$5.53M Sell
203,884
-73,210
-26% -$2.07M 0.02% 981
2015
Q2
$7.59M Sell
277,094
-4,248
-2% -$119K 0.02% 962
2015
Q1
$7.51M Sell
281,342
-24,156
-8% -$556K 0.02% 977
2014
Q4
$6.46M Sell
305,498
-32,014
-9% -$715K 0.02% 1012
2014
Q3
$8.04M Sell
337,512
-15,140
-4% -$348K 0.02% 986
2014
Q2
$8.14M Buy
352,652
+22,820
+7% +$504K 0.02% 949
2014
Q1
$7.53M Buy
329,832
+176,562
+115% +$3.76M 0.02% 946
2013
Q4
$2.83M Buy
153,270
+111,400
+266% +$1.94M 0.01% 1481
2013
Q3
$709K Buy
41,870
+21,560
+106% +$363K ﹤0.01% 2275
2013
Q2
$315K Buy
+20,310
New +$338K ﹤0.01% 2599

Other funds holding NVO

Guggenheim Capital's NVO Position: Q2 2026 in Review

Guggenheim Capital reduced its Novo Nordisk (NVO) stake by 9.7% in Q2 2026, selling an estimated $147K and leaving 31,709 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #839.

Guggenheim Capital first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.14M in Q2 2014. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Guggenheim Capital held 31,709 shares of Novo Nordisk worth $1.52M as of Q2 2026.
  • Guggenheim Capital sold 3,411 Novo Nordisk shares in Q2 2026, an estimated $147K.
  • Novo Nordisk made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #839 holding.
  • Guggenheim Capital first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Guggenheim Capital's Novo Nordisk position peaked at $8.14M in Q2 2014.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.